Analysts' Viewpoints: Sarepta Therapeutics (SRPT), Kirby (KEX), Nautilus (NLS), Pengrowth Energy (PGH), Fresnillo (FNLPF)
Analysts at RBC Capital Markets boosted their price target on Sarepta Therapeutics, Inc. (Nasdaq:SRPT) shares from $83.00 to $108.00, while maintaining an Outperform rating
Sarepta Therapeutics is focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.
Brokerage firm Stifel reiterated a Hold rating on shares of Kirby Corp. (NYSE:KEX) while increasing its price target to $54.00 from $50.00
Kirby is a domestic tank barge operator, transporting bulk liquid products. The Company, through its subsidiaries, operates in two segments: Marine Transportation and Diesel Engine Services.
Equities researchers at Wunderlich maintained a Buy rating on Nautilus, Inc. (NYSE:NLS) and raised their price objective from $24.00 to $28.00 per share
Nautilus is a consumer fitness products company. It operates through two segments: Direct and Retail.
Pengrowth Energy Corp. (NYSE:PGH) had its price target increased by RBC Capital Markets from $1.25.00 to $1.50 per share. The investment firm currently has an Underperform rating on the stock
Pengrowth Energy, a resource company, is engaged in the production, development, exploration and acquisition of oil and natural gas assets.
Investment analysts at Morgan Stanley upgraded Fresnillo PLC (OTCMKTS:FNLPF) from an Underweight to an Equal-Weight rating
Fresnillo is engaged in the mining and beneficiation of non-ferrous minerals, and the sale of related production. The primary contents of this production include silver, gold, lead and zinc
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer